Costs
Science News
- Suppression of the Prostaglandin I2–Type 1 Interferon Axis Induces Extramedullary Hematopoiesis to Promote Cardiac Repair after Myocardial Infarction May 6, 2025To assess the role of spleen extramedullary hematopoiesis (EMH) in myocardial infarction (MI), scientists constructed a Tcf21CreER Scfflox/flox MI mouse model with inhibited EMH. [Circulation] Full Article
- Overexpressing Natural Killer Group 2 Member a Drives Natural Killer Cell Exhaustion in Relapsed Acute Myeloid Leukemia May 6, 2025[Signal Transduction and Targeted Therapy] Researchers investigated NK cell exhaustion in relapsed AML patients following allogeneic hematopoietic stem cell transplantation through phenotypic assessments, functional assays, and RNA sequencing analyses.
- PIEZO1 Activation-Mediated Generation of Transgene-Free Long-Term Hematopoietic Stem Cells May 6, 2025[American Journal of Hematology] Investigators found that pulsation-mediated circumferential stretch was restricted to the ventral part of the dorsal aorta and activated Piezo1 to stimulate long-term reconstituting hematopoietic stem cells formation.
- Outcomes of Allogeneic Haemopoietic Transplant for Chronic Lymphocytic Leukaemia in the Modern Era May 6, 2025[Internal Medicine Journal] Scientists examined the use of HSCT performed for chronic lymphocytic leukaemia in Australia and New Zealand, including patients exposed to pathway inhibitors prior to transplant.
- Emerging Therapeutic Approaches for Anemia in Myelofibrosis May 6, 2025[Current Hematologic Malignancy Reports] The authors highlight conventional agents and novel emerging therapeutic strategies to treat anemia in myelofibrosis.
- CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase I Clinical Trial of CER-1236 in Acute Myeloid Leukemia May 6, 2025[CERo Therapeutics, Inc.] CERo Therapeutics Holdings, Inc. announced that TriStar Centennial Medical Center, through Sarah Cannon Research Institute, in Nashville, Tennessee, is a clinical trial site for the Company’s Phase I clinical of CER-1236.
- U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) May 5, 2025[Abeona Therapeutics, Inc.] Abeona Therapeutics, Inc. announced the US FDA has approved ZEVASKYN™ gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.
- ZNF224 Enhances the Oncogenic Function of P21 via P53 and AKT Pathways in Melanoma May 5, 2025[FEBS Journal] Scientists investigated the molecular mechanisms underlying the oncogenic role of zinc finger protein 224 (ZNF224) in melanoma.
- Molecular and Immune Landscape of Melanoma: A Risk Stratification Model for Precision Oncology May 5, 2025[Discover Oncology] Investigators provided a robust immune-related prognostic model for melanoma. They underscored the value of immune gene expression and T cell infiltration, particularly CD8+ T cells, in predicting patient outcomes.
- Investigating the Properties of Truncal Acne: A Common but Often Overlooked Entity May 5, 2025[Journal of Cutaneous Medicine and Surgery] Researchers investigated the prevalence of truncal acne in patients with mild, moderate, and severe acne and evaluated the characteristics of truncal acne.